A Population Pharmacokinetic Model of Linezolid enabling Model-Informed Precision Dosing in Patients with Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis

Background: Multidrug-resistant (MDR) tuberculosis (TB) is still a global health threat with close to half a million new cases annually (1). Infection with MDR- or extensively drug resistant (XDR-) TB requires usage of second-line treatment, which is longer, requires costly, more toxic drugs and has a success rate of merely 56% (1). Linezolid is one […]